Compare Illumina, Inc. (ILMN) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nasdaq Inc — how do they compare? Illumina, Inc. trades at $190.86 (market cap $29.12B), while Nasdaq Inc trades at $95.62 (market cap $53.11B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Nasdaq Inc pays a 1.22% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NDAQ | |
|---|---|---|
Market Cap | $29.12B | $53.11B |
Sector | Health | Financials |
52-Week High | $205.10 | $100.98 |
52-Week Low | $91.00 | $76.85 |
Enterprise Value | $30.48B | $59.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Nasdaq (NDAQ) trades at $95.26, down 0.38% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $8.26B in 2025, with net income reaching $1.79B and a profit margin of 21.64%. The company has beaten EPS estimates in recent quarters and announced the acquisition of LeveL Markets to expand its market infrastructure. Analyst consensus is strongly positive, with a $109.20 price target indicating ~15% upside.
Outlook remains favorable driven by earnings growth and strategic acquisitions, though risks include market volatility and integration challenges. The stock offers value through consistent profitability and dividend payments, supported by institutional confidence. Investors should weigh execution risks against the potential for continued expansion in financial services technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
